Psychopharmacology

, Volume 221, Issue 4, pp 601–610 | Cite as

Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder

  • Robert Riesenberg
  • Joshua Rosenthal
  • Leslie Moldauer
  • Christine Peterson
Original Investigation

Abstract

Background

RX-10100 (Serdaxin®), a nonantibiotic small molecule beta-lactam compound, has shown potent antidepressant and anxiolytic activities in preclinical models. RX-10100 does not bind to the serotonin transporter or other receptors associated with monoamine activity. In microdialysis studies with rats, RX-10100 increased the release of dopamine and serotonin metabolites. A clinical proof-of-concept study was conducted to determine the clinical effectiveness of RX-10100 in treating depression.

Methods

This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study of people with depression (n = 77; HAM-D-17 baseline score ≥ 20). Eligible subjects were randomly assigned to receive RX-10100 (5, 10, or 15 mg twice daily) or placebo for 8 weeks. Change from baseline in the MADRS total score was the primary endpoint.

Results

Mean changes in MADRS scores were −46.0%, −37.9%, and −41.4%, for 5, 10, and 15 mg RX-10100, respectively, as compared with 43.1% for placebo. In subjects with severe depression (baseline MADRS ≥ 29; n = 28) scores improved 55.6% with 5 mg RX-10100 but only 34% with placebo (p = 0.041). In an analysis of responders (i.e., subjects with 50% change from baseline score), 64.3% of subjects treated with 5 mg RX-10100 responded. All doses of RX-10100 were well-tolerated.

Conclusion

In this proof-of-concept study, RX-10100 treatment (5 mg twice daily) improved MADRS scores in subjects with severe depression. RX-10100 does not appear to have many of the typical side effects of other antidepressants. These results indicate a need for larger studies further evaluating RX-10100 at 5 mg and lower doses.

Keywords

Depression Antidepressant Hippocampus Serotonin Serotonergic Dopamine Dopaminergic Anxiety Microdialysis 

Notes

Conflicts of interests

This study was registered at www.clinicaltrials.gov trial identifier: NCT00839176. This study was financially supported by Rexahn Pharmaceuticals, Inc. who designed, conducted, analyzed the study results and wrote the reports. All authors contributed to and approved the final manuscript. Drs. Riesenberg, Rosenthal and Moldauer have no conflicts of interest to declare. Dr. Peterson is employed by Rexahn Pharmaceuticals, Inc.

References

  1. Bostwick JM (2010) A generalist’s guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc 85(6):538–550PubMedCrossRefGoogle Scholar
  2. Chan JS, Kim DJ, Ahn CH, Oosting RS, Olivier B (2009) Clavulanic acid stimulates sexual behavior in male rats. Eur J Pharmacol 609(1–3):69–73PubMedCrossRefGoogle Scholar
  3. Clayton AH, Croft HA, Horrigan JP et al (2006) Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 67(5):736–746PubMedCrossRefGoogle Scholar
  4. Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA (2010 Dec 13) Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety [Epub ahead of print]Google Scholar
  5. Jefferson JW, Rush AJ, Nelson JC et al (2006) Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67(6):865–873PubMedCrossRefGoogle Scholar
  6. Kim DJ, King JA, Zuccarelli L et al (2009) Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacol Biochem Behav 93(2):112–120PubMedCrossRefGoogle Scholar
  7. Kivimäki M, Hamer M, Batty GD et al (2010) Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 33(12):2611–2616PubMedCrossRefGoogle Scholar
  8. Knoth RL, Bolge SC, Kim E, Tran QV (2010) Effect of inadequate response to treatment in patients with depression. Am J Manag Care 16(8):e188–e196PubMedGoogle Scholar
  9. Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB (2011) Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. Neurosci Lett 504(2):170–175Google Scholar
  10. Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005) Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59(3):268–275PubMedCrossRefGoogle Scholar
  11. McClintock SM, Husain MM, Wisniewski SR et al (2011) Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Clin Psychopharmacol 31(2):180–186CrossRefGoogle Scholar
  12. McIntyre RS (2010) When should you move beyond first-line therapy for depression? J Clin Psychiatry 71(Suppl 1):16–20Google Scholar
  13. Rubin RR, Ma Y, Peyrot M et al (2010) Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes stud. Diabetes Care 33(12):2549–2551PubMedCrossRefGoogle Scholar
  14. Serretti A, Chiesa A (2011) Sexual side effects of pharmacological treatment of psychiatric diseases. Clin Pharmacol Ther 89(1):142–147PubMedCrossRefGoogle Scholar
  15. Serretti A, Mandelli L (2010) Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 71(10):1259–1272PubMedCrossRefGoogle Scholar
  16. Stranieri G (2010) Psychopharmacology of depression and sexual disorders. Psychiatr Danub 22(Suppl 1):S68–S71PubMedGoogle Scholar
  17. Velligan D, Sajatovic M, Valenstein M, et al (2010) Methodological challenges in psychiatric treatment adherence research. Clin Schizophr Relat Psychoses (1):74-91Google Scholar
  18. Warden D, Rush AJ, Wisniewski SR et al (2009) What predicts attrition in second step medication treatments for depression?: a STAR*D report. Int J Neuropsychopharmacol 12(4):459–473PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Robert Riesenberg
    • 1
  • Joshua Rosenthal
    • 2
  • Leslie Moldauer
    • 3
  • Christine Peterson
    • 4
  1. 1.Atlanta Center for Medical ResearchAtlantaUSA
  2. 2.Capital Clinical Research AssociatesRockvilleUSA
  3. 3.Segal Institute for Clinical ResearchMiamiUSA
  4. 4.Rexahn Pharmaceuticals, Inc.RockvilleUSA

Personalised recommendations